Ozempic for Diabetes: How It Works in the UK

Ozempic for diabetes is a once-weekly injectable treatment containing semaglutide, licensed by the MHRA for adults with type 2 diabetes in the UK. As a GLP-1 receptor agonist, it works by stimulating insulin release, suppressing glucagon, and slowing gastric emptying to improve long-term blood glucose control. Beyond glycaemic management, clinical evidence supports cardiovascular benefits in those with established heart disease. This article explains how Ozempic works, who qualifies for it on the NHS, how to use it correctly, and which side effects to monitor.

What is Ozempic and how does it work for diabetes?

Ozempic is a once-weekly semaglutide injection that lowers blood glucose by stimulating insulin release, suppressing glucagon, and slowing gastric emptying. It also reduces cardiovascular risk in people with established heart disease, as reflected in NICE NG28 guidance.

Ozempic is a once-weekly injectable medicine containing semaglutide, licensed in the UK by the MHRA for the treatment of type 2 diabetes in adults.^[1][2] It belongs to a class of medicines called glucagon-like peptide-1 (GLP-1) receptor agonists, which mimic the action of a naturally occurring gut hormone released after eating.^[16][8]

The mechanism works on several levels. Ozempic stimulates the pancreas to release insulin in response to raised blood glucose, while simultaneously suppressing glucagon, a hormone that would otherwise raise blood sugar levels.^[1][2] It also slows gastric emptying, which reduces the speed at which glucose enters the bloodstream after a meal.^[17][18] Together, these actions help to lower HbA1c, the key marker of long-term blood glucose control.

Beyond glucose management, clinical evidence has shown that semaglutide is associated with reductions in body weight and, in people with established cardiovascular disease, a reduction in the risk of major cardiovascular events such as heart attack and stroke. These broader benefits are reflected in NICE guidance on its use within the NHS (NICE NG28: Type 2 diabetes in adults: management).

It is worth noting that Ozempic is distinct from Wegovy, which also contains semaglutide but is licensed specifically for chronic weight management at doses up to 2.4 mg weekly, with a higher licensed ceiling of 7.2 mg also authorised by the MHRA. Ozempic is licensed for type 2 diabetes and is not interchangeable with Wegovy, even though both contain the same active ingredient.

Who can be prescribed Ozempic for diabetes in the UK?

Ozempic is prescribed for adults with type 2 diabetes whose blood glucose remains inadequately controlled despite existing treatment, guided by NICE NG28 criteria. It is particularly relevant where cardiovascular risk reduction or minimising hypoglycaemia are clinical priorities.

Ozempic can be prescribed for adults with type 2 diabetes whose blood glucose is not adequately controlled despite existing treatment, typically when used alongside metformin or other oral antidiabetic medicines, or as monotherapy when those medicines are not tolerated. NICE NG28 (Type 2 diabetes in adults: management) sets out the clinical criteria that inform NHS prescribing, and local Integrated Care Boards (ICBs) make commissioning decisions based on those recommendations.^[3][4]

In practice, Ozempic is most commonly considered when:

• HbA1c remains above the agreed target despite optimised oral therapy

• There is a need to minimise hypoglycaemia risk, as semaglutide carries a low intrinsic risk of low blood sugar when used without insulin or a sulphonylurea

• The person has established cardiovascular disease, where the cardiovascular benefits of semaglutide are particularly relevant

• Weight management is an additional clinical priority alongside glucose control

The only formal contraindication listed in the UK SmPC is hypersensitivity to semaglutide or any excipient. Ozempic is not licensed for type 1 diabetes. Prescribers will take a full medical history, including any history of pancreatitis or diabetic eye disease, before initiating treatment. No dose adjustment of Ozempic itself is required for renal impairment, though experience in severe renal impairment is limited; prescribers may need to reduce the dose of any concomitant sulphonylurea or insulin to lower the risk of hypoglycaemia.^[1][2]

For those seeking an online consultation, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering weight-management and diabetes-related consultations, with prescriber review and pharmacist support, where a medicine such as Ozempic may be considered if it is clinically appropriate.

How do you use Ozempic and what dose will you start on?

Ozempic is injected subcutaneously once weekly, starting at 0.25 mg for four weeks to aid tolerability, then increasing to 0.5 mg, 1 mg, or up to 2 mg weekly based on glycaemic response. Injection sites should be rotated and pens stored in a refrigerator before first use.

Ozempic is administered as a subcutaneous injection once a week, on the same day each week, into the abdomen, thigh, or upper arm. The starting dose is 0.25 mg once weekly for the first four weeks, which is an introductory dose intended to improve tolerability rather than to achieve full therapeutic effect.

After four weeks, the dose is increased to 0.5 mg once weekly. If further blood glucose control is needed after at least four weeks at 0.5 mg, the dose may be increased to 1 mg once weekly. The UK SmPC also provides for a further increase to 2 mg once weekly if additional glycaemic control is required after at least four weeks at 1 mg. The maximum licensed dose of Ozempic for type 2 diabetes is 2 mg weekly.

Ozempic comes as a pre-filled pen device. Each pen contains multiple doses, and patients are required to attach a new pen needle before each injection. The injection site should be rotated with each dose to reduce the risk of skin reactions at the site. Pens should never be shared between patients, even if the needle is changed, and used needles should be disposed of in an approved sharps container. Ozempic should be stored in a refrigerator (2°C to 8°C) before first use; after first use, it can be kept at room temperature below 30°C or in the refrigerator for up to 56 days.^[1][2]

The UK SmPC notes that semaglutide may transiently delay the absorption of oral medicines taken at the same time, due to its effect on gastric emptying. Women taking oral contraceptives should discuss this with their prescriber, who can advise on whether any additional contraceptive precautions are appropriate. Ozempic should not be used during pregnancy or breastfeeding. Women planning a pregnancy should discuss stopping the medicine with their doctor in advance; the SmPC recommends stopping semaglutide at least two months before a planned conception.^[1][2]

What side effects should you watch out for with Ozempic?

The most common side effects are gastrointestinal, including nausea, vomiting, and diarrhoea, which typically improve over time. Serious but less common risks include pancreatitis, gallbladder disease, worsening diabetic retinopathy, and dehydration-related kidney effects.

The most commonly reported side effects of Ozempic are gastrointestinal in nature, particularly during the dose escalation phase. These include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. For most people, these effects are mild to moderate and tend to improve over time as the body adjusts to the medicine. Eating smaller, low-fat meals and avoiding large portions can help reduce nausea.

More serious but less common effects to be aware of include:

• Pancreatitis: Acute pancreatitis has been reported in people taking semaglutide, including post-marketing reports of necrotising pancreatitis and cases with fatal outcomes.^[19][1] If you develop persistent, severe abdominal pain that may radiate to the back, stop taking Ozempic and seek urgent medical attention via 999 or your nearest A&E.

• Gallbladder disease: Cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) have been reported with semaglutide.^[20][21] If you develop upper abdominal pain, particularly after eating, fever, or jaundice, seek prompt medical advice.

• Diabetic retinopathy: A transient worsening of pre-existing diabetic eye disease, particularly in those with pre-proliferative or proliferative retinopathy, has been observed, especially when blood glucose is lowered rapidly.^[22][23] People with known diabetic eye disease should have this monitored closely.

• Hypoglycaemia: The risk is low with Ozempic alone but increases when it is combined with insulin or a sulphonylurea.

• Dehydration and kidney effects: Persistent vomiting or diarrhoea can lead to dehydration, which may in turn affect kidney function. If you are unable to keep fluids down or have signs of dehydration such as dizziness, reduced urination, or feeling faint, seek medical advice promptly.

• Injection site reactions: Redness, bruising, or discomfort at the injection site can occur.

If you experience any unexpected or concerning symptoms, contact your GP or call NHS 111 for advice. Suspected side effects can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Healthcare professionals and patients are both encouraged to report, as this supports ongoing medicine safety monitoring in the UK.

Frequently Asked Questions